Welcome to our dedicated page for Sagimet Biosciences news (Ticker: SGMT), a resource for investors and traders seeking the latest updates and insights on Sagimet Biosciences stock.
Sagimet Biosciences Inc. (NASDAQ: SGMT) is a clinical-stage biopharmaceutical company developing oral fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne. The news flow around SGMT reflects its progress in clinical development, licensing collaborations, and capital markets activity.
Company announcements frequently highlight clinical trial milestones for its lead candidate denifanstat, including results from the Phase 2b FASCINATE-2 trial in MASH and Phase 3 acne data generated by its license partner in China. News items also cover secondary analyses using AI-based digital pathology and spatial computational histology to characterize fibrosis and treatment response in advanced MASH, as well as updates on a Phase 1 pharmacokinetic trial combining denifanstat with the thyroid hormone receptor beta agonist resmetirom.
Investors following SGMT news can also expect updates on Sagimet’s second oral FASN inhibitor, TVB-3567, which is in a Phase 1 first-in-human trial and is planned for acne development. Additional coverage includes regulatory interactions such as China’s National Medical Products Administration acceptance of a New Drug Application for denifanstat (ASC40) in acne, and Sagimet’s own disclosures about Breakthrough Therapy designation and end-of-Phase 2 interactions for denifanstat in MASH.
Beyond clinical and regulatory developments, Sagimet issues news on its license agreement with TAPI for innovative forms of resmetirom API to support a fixed-dose combination program, participation in healthcare and liver disease conferences, and periodic financial and corporate updates reported via Form 8-K. This news page aggregates those press releases and related items so readers can track the evolution of Sagimet’s FASN inhibitor pipeline and key events affecting SGMT stock.
Sagimet Biosciences (SGMT) has successfully completed end-of-Phase 2 interactions with the FDA for denifanstat in metabolic-dysfunction associated steatohepatitis (MASH). The company plans to initiate two Phase 3 trials by end of 2024: FASCINATE-3 for F2/F3 non-cirrhotic MASH patients, focusing on liver biopsy and 4.5-year clinical outcomes, and FASCINIT for MASLD/MASH patients, evaluating safety and tolerability. The Phase 3 program will include a minimum of 1,800 patients exposed to denifanstat.
Sagimet Biosciences (Nasdaq: SGMT) announced three presentations at the AASLD - The Liver Meeting® 2024 in San Diego, showcasing data on their fatty acid synthase (FASN) inhibitor, denifanstat. The presentations include:
1. An oral presentation on AI-based digital pathology results from the FASCINATE-2 study, demonstrating denifanstat's improvement of fibrosis parameters and reduction of progression to cirrhosis in MASH patients.
2. A poster on denifanstat's reduction of atherosclerosis development in a mouse model of dyslipidaemia and MASH, suggesting potential cardiovascular and liver health benefits.
3. A poster highlighting denifanstat's significant improvement of liver fibrosis in difficult-to-treat MASH patients, based on conventional and AI-based pathology from the Phase 2b FASCINATE-2 trial.
These presentations underscore denifanstat's potential as a novel therapeutic for metabolic and fibrotic pathways in liver disease.
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohepatitis (MASH) and stage 2 or 3 fibrosis, showed statistically significant and clinically meaningful improvements in disease activity, MASH resolution, and fibrosis.
Key findings include:
- 36% of denifanstat-treated patients achieved MASH resolution without worsening of fibrosis (vs 13% with placebo)
- 52% of denifanstat-treated patients showed ≥2-point reduction in NAS without worsening of fibrosis (vs 20% with placebo)
- 41% of denifanstat-treated patients demonstrated fibrosis improvement by ≥ 1 stage without worsening of steatohepatitis (vs 18% with placebo)
The results support the advancement of denifanstat into Phase 3 development, with Sagimet planning to start their Phase 3 program in 2024.
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced that the FDA has granted Breakthrough Therapy designation to denifanstat for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. This designation was supported by positive data from the Phase 2b FASCINATE-2 trial, where denifanstat showed statistically significant improvements in MASH resolution and fibrosis reduction. The company plans to initiate a Phase 3 clinical program for denifanstat in MASH by the end of 2024.
Denifanstat, as the only fat synthesis inhibitor targeting the three main drivers of MASH (fat accumulation, inflammation, and fibrosis), demonstrated efficacy in meeting primary and secondary endpoints in the trial. The treatment was generally well-tolerated, positioning it as a potential leading treatment option for MASH patients.
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors, announced two key updates:
1. Management will participate in a virtual fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference on October 7, 2024, at 2:30 PM ET. A live webcast will be available on Sagimet's website.
2. The company approved inducement grants for four newly-hired employees, consisting of stock options to purchase shares of Sagimet's Series A common stock with a total aggregate value of $611,000. These options, granted under Nasdaq Rule 5635(c)(4), have a ten-year term and vest over four years, with specific vesting conditions based on continued service.
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced an upcoming oral presentation at the 8th Annual MASH Drug Development Summit in Boston, scheduled for September 24-26, 2024. The presentation, titled "Demonstrating denifanstat's differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity," will be given by Dr. Marie O'Farrell, Senior Vice President of Research and Development at Sagimet.
The presentation will highlight denifanstat's anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH). It is part of the session "Showcasing Antifibrotic Progress, Past Learnings & Innovations to Supercharge MASH Drug Development" and is scheduled for Thursday, September 26, 2024, from 4:15 to 4:45 PM ET.
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors, announced its participation in two upcoming investor conferences. The company will engage in fireside chats at:
- The H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 11:00 a.m. ET in New York
- The 2024 Cantor Global Healthcare Conference on September 17, 2024, at 9:10 a.m. ET in New York
Webcasts of both events will be available on Sagimet's website, with replays accessible for 90 days after the live events. These conferences provide Sagimet an opportunity to showcase its progress in developing novel therapies targeting dysfunctional metabolic and fibrotic pathways.
Sagimet Biosciences (Nasdaq: SGMT) reported Q2 2024 financial results and corporate updates. Key highlights include:
1. Presentation of denifanstat Phase 2b FASCINATE-2 52-week data at EASL Congress, showing significant fibrosis reduction in advanced F2 and F3 patients.
2. Preparations for Phase 3 clinical development of denifanstat in MASH patients in H2 2024.
3. Appointment of two biotech industry leaders to the Board of Directors.
4. Cash position of $188.5 million as of June 30, 2024, expected to fund operations through 2025.
5. Q2 2024 financial results: R&D expense $6.3 million, G&A expense $4.3 million, net loss $8.1 million.
Sagimet Biosciences Inc. (Nasdaq: SGMT) has appointed Anne Phillips and Jennifer Jarrett to its Board of Directors, effective August 1, 2024. This strategic move comes as Sagimet prepares to initiate Phase 3 clinical development of denifanstat in MASH this year. Dr. Phillips brings over 25 years of pharmaceutical industry experience, including regulatory affairs expertise from her tenure at Novo Nordisk. Ms. Jarrett contributes significant financial and operational experience from her roles at Arcus Biosciences and Uber. Both appointees express enthusiasm for Sagimet's potential, particularly regarding denifanstat's unique fat synthesis inhibition mechanism for addressing MASH. These additions aim to strengthen Sagimet's leadership as it advances its pipeline of FASN-directed therapeutics.
Sagimet Biosciences, a clinical-stage biopharmaceutical company, announced a conference call and webcast on June 13, 2024, at 9:30 AM PT / 12:30 PM ET to discuss data from their Phase 2b FASCINATE-2 clinical trial.
The trial evaluates denifanstat, an oral, once-daily FASN inhibitor, in metabolic dysfunction-associated steatohepatitis (MASH) patients. Dr. Rohit Loomba will present the data, which was recently shared at the EASL Congress in Milan, Italy.
Participants can join the live event via webcast or dial-in using provided numbers. A chat-based Q&A session will follow the presentation.